New pill combo aims to keep childhood leukemia away after transplant
NCT ID NCT07012044
First seen Jan 28, 2026 · Last updated May 15, 2026 · Updated 21 times
Summary
This early-phase study tests whether an oral drug called ASTX727 (which combines cedazuridine and decitabine) plus a shot called filgrastim can safely help prevent leukemia from coming back in children who have already had a stem cell transplant for high-risk acute myeloid leukemia (AML). The study enrolls up to 47 children and teens up to age 21 whose leukemia returned or didn't respond to prior treatment. The main goals are to find the best dose and check for side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Children's Hospital of Philadelphia
RECRUITINGPhiladelphia, Pennsylvania, 19104, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Saint Jude Children's Research Hospital
RECRUITINGMemphis, Tennessee, 38105, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.